Cancer Diagnostics – News and Features

A model based on artificial intelligence is able to predict the therapy outcome in 80% of ovarian cancer patients. The tool, named IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy), analyzes various patient clinical features.

In this opinion piece, Neil Ward explores how advances in sequencing could help to provide new insights for rare disease patients.

A liquid biopsy that identifies cell-free DNA as a marker of cancer could improve cancer detection in patients with Li-Fraumeni syndrome, which carries an almost 100 percent lifetime risk of developing cancer.

A team of scientists at Stanford University has taken a look inside the human eye with a new level of detail by using cutting-edge molecular analysis.

A new method for selecting aptamers, or "chemical antibodies," created by Penn State engineers takes only days to complete, instead of the months typically needed for traditional methods.

The Association for Molecular Pathology has published a set of 13 best practice recommendations for validating and reporting clinical circulating tumor DNA or liquid biopsy assays and their related scientific publications.

A new study on human tissue and plasma shows the blood test may distinguish between cancerous and benign pelvic masses with up to 91% accuracy, surpassing other commercially available tests.

Measuring ctDNA could offer a new approach to identifying non-small cell lung cancer patients in greater need of additional treatments during immunotherapy.

The midbody remnant – a signaling organelle that forms during mitosis – has been shown to be packed with genetic material that can play a role in cancer development.

Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.